NEW YORK ( TheStreet) -- TheStreet's Debra Borchardt is with Francis Gaskins, Director of Research for Equities.com, discussing the three biotech IPOs this week.BlueBirdBio (BLUE - Get Report) has a $75 million offering and just completed a deal with Celgene (CELG - Get Report), which bodes well for the company, Gaskins says.
Quick Take: Drugs IPOs Depend on Deals
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.